Clinical Trials Browser

Phase 1/2 × erdafitinib × Gastrointestinal × Clear all

NCT02421185 2025-02-03

Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma

Phase 1/2 Completed

Gastrointestinal

Carcinoma, Hepatocellular